You have free access to this content

Cancer

Cover image for Cancer

15 November 2002

Volume 95, Issue 10

Pages 2041–2255

  1. Editorial

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    1. General Topic

      You have free access to this content
      How to compare results after surgery or radiation for localized prostate carcinoma : Prostate specific antigen (PSA) outcome (No), posttreatment PSA doubling time (Maybe), or survival (Yes)? (pages 2041–2043)

      Anthony V. D'Amico

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10912

      In addressing the clinically relevant question regarding prostate specific antigen (PSA) outcome data in the study presented by Vicini and colleagues in this issue of Cancer, the author concurs with Vicini et al. that only a randomized trial powered to assess survival ultimately can answer the important question of the relative efficacy of surgery versus various forms of radiation therapy in the management of patients with localized prostate carcinoma. In addition, the author points out that one posttreatment clinical parameter, the posttreatment PSA doubling time, has emerged from both the surgical literature and the radiation literature as a potential candidate for predicting the likelihood of death from prostate carcinoma after primary treatment failure.

      See also pages 2126–35.

  2. Original Articles

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma (pages 2044–2050)

      Chiun Hsu, Chiun-Sheng Huang, Tsu-Yi Chao, Yen-Shen Lu, Ching-Fang Bu, Mary M. Chen, King-Jeng Chang and Ann-Lii Cheng

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10951

      A chemotherapeutic regimen combining paclitaxel with a 24-hour infusion of cisplatin was tested in 28 patients with locally advanced breast carcinoma and 18 patients with metastatic breast carcinoma. There were 3 complete responses and 24 partial responses, with an overall response rate of 58.7%. The treatment-related toxicities were relatively mild.

    2. You have free access to this content
      Factors influencing mortality among young women with second primary breast carcinoma (pages 2051–2058)

      Jonine L. Bernstein, Robert Lapinski, Charles Lynch, Theodore Holford and W. Douglas Thompson

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10950

      This prospective cohort study provided little evidence that important etiologic factors for breast carcinoma predict mortality following diagnosis of a second primary breast carcinoma after adjusting for characteristics of the tumor and age at diagnosis.

    3. You have free access to this content
      Classifying local disease recurrences after breast conservation therapy based on location and histology : New primary tumors have more favorable outcomes than true local disease recurrences (pages 2059–2067)

      Eugene Huang, Thomas A. Buchholz, Funda Meric, Savitri Krishnamurthy, Nadeem Q. Mirza, Frederick C. Ames, Barry W. Feig, Henry M. Kuerer, Merrick I. Ross, S. Eva Singletary, Marsha D. McNeese, Eric A. Strom and Kelly K. Hunt

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10952

      After breast conservation therapy, patients who developed new primary breast tumors had significantly better survival than those with true local disease recurrences, but were more likely to develop contralateral breast carcinoma. This distinction may have importance in therapeutic decisions and chemoprevention strategies.

    4. You have free access to this content
      HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry (pages 2068–2075)

      Louise A. Quenneville, Kelly-Anne Phillips, Hilmi Ozcelik, Robert K. Parkes, Julia A. Knight, Pamela J. Goodwin, Irene L. Andrulis and Frances P. O'Malley

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10949

      Invasive breast carcinomas in Ashkenazi BRCA1 mutation carriers are more frequently high grade, estrogen receptor negative, and negative for HER-2/neu protein overexpression. Controlling for grade, there is no difference between Ashkenazi carriers and noncarriers with respect to progesterone receptor status, degree of mononuclear inflammatory cell infiltrate, circumscribed margins, syncytical growth, lymph node status, lymphatic vessel invasion, or in the presence of ductal carcinoma in situ associated with the invasive tumors.

    5. Endocrine Disease
      You have free access to this content
      Long-term outcome of patients with insular carcinoma of the thyroid : The insular histotype is an independent predictor of poor prognosis (pages 2076–2085)

      Gabriella Pellegriti, Dario Giuffrida, Claudia Scollo, Riccardo Vigneri, Concetto Regalbuto, Sebastiano Squatrito and Antonino Belfiore

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10947

      The outcome of patients with insular carcinoma was compared with that of patients with differentiated thyroid carcinoma with similar age and tumor size. The authors provide clinical evidence that justifies classifying insular thyroid carcinoma as a separate clinicopathologic entity with aggressive behavior, and it is suggested that patients with these tumors should be treated with combined modalities.

    6. Gastrointestinal Tract
      You have free access to this content
      Overexpression of the insulin-like growth factor I receptor in human colon carcinomas (pages 2086–2095)

      Matthias M. Weber, Christian Fottner, Sun Bin Liu, M. Christina Jung, Dieter Engelhardt and Gustavo B. Baretton

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10945

      A majority of primary colon carcinomas overexpress IGF-I receptor, both at the protein and mRNA level, in comparison to paired normal colon tissue.

    7. You have free access to this content
      Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States (pages 2096–2102)

      Ai Kubo and Douglas A. Corley

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10940

      There are substantial regional, temporal, and ethnic differences between esophageal adenocarcinoma and gastric cardia adenocarcinoma incidence rates within the United States. These findings suggest that these adenocarcinomas may differ in important ways. Studies on an individual level are needed to explain these substantial regional and ethnic differences.

    8. You have free access to this content
      Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma (pages 2103–2111)

      Ralf Gertler, Robert Rosenberg, Dominik Stricker, Martin Werner, Silke Lassmann, Kurt Ulm, Hjalmar Nekarda and Joerg-Ruediger Siewert

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10939

      Human telomerase reverse transcriptase (hTERT) expression was quantified in samples of colorectal carcinoma and matched nontumorous mucosa from 57 patients using real-time reverse transcriptase-polymerase chain reaction analysis, and the results were correlated with histopathologic tumor parameters and with survival. In the current study, the authors demonstrate the potential of hTERT as a molecular marker for biologic and prognostic tumor staging.

    9. Genitourinary Disease
      You have free access to this content
      The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1–10.0 ng/mL (pages 2112–2119)

      Kazuto Ito, Masaru Ohi, Takumi Yamamoto, Shigeto Miyamoto, Kohei Kurokawa, Yoshitatsu Fukabori, Kazuhiro Suzuki and Hidetoshi Yamanaka

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10941

      The age-adjusted and prostate volume-adjusted biopsy method for the detection of prostate carcinoma was more useful compared with the traditional six-sextant biopsy method. The authors recommend the use of this adjusted biopsy method, especially for men age ≤ 64 years, men with large prostate volumes (≥ 50 cc), and men with prostate specific antigen density levels ≤ 0.15 ng/mL/cc.

    10. You have free access to this content
      Prognostic significance of thymidine kinase activity in bladder carcinoma (pages 2120–2125)

      Yoichi Mizutani, Hiromi Wada, Osamu Yoshida, Masakazu Fukushima, Kazumi Kamoi and Tsuneharu Miki

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10948

      Thymidine kinase (TK) activity was correlated with both disease stage and tumor grade in patients with carcinoma of the urinary bladder. In addition, elevated TK activity predicted early recurrence in patients with bladder carcinoma who had Ta and T1 disease.

    11. You have free access to this content
      An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up (pages 2126–2135)

      Frank A. Vicini, Alvaro Martinez, Gerald Hanks, Alex Hanlon, Brian Miles, Ken Kernan, David Beyers, Haakon Ragde, Jeffrey Forman, James Fontanesi, Larry Kestin, Gyorgy Kovacs, Louis Denis, Kevin Slawin and Peter Scardino

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10919

      The authors conducted a retrospective study of men with prostate carcinoma and found that 5-year prostate specific antigen results were remarkably similar for groups of low-risk patients and intermediate-risk patients, regardless of the form of therapy used. The study indicated that interinstitutional and interspecialty comparisons of treatment outcomes for patients with prostate carcinoma are possible but that, to be meaningful, the results must be based on all major prognostic variables.

      See also pages 2041–3.

    12. You have free access to this content
      Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma (pages 2136–2144)

      Zhao Chen, Michael Maricic, Paul Nguyen, Frederick R. Ahmann, Roberta Bruhn and Bruce L. Dalkin

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10967

      The authors investigated the risk of osteoporosis and obesity among men with prostate carcinoma who were treated with androgen deprivation therapy (ADT) in a case–control study. The cases were 62 men with prostate carcinoma who had been receiving ADT for 1–5 years and the controls were 47 healthy men with prostate specific antigen levels < 4.0 ng/mL who had never been diagnosed with prostate carcinoma. The study results indicated that the prostate carcinoma cases were more likely to be osteoporotic and obese compared with the controls. This finding demonstrates the need for research and medical attention to prevent and manage bone loss and unhealthy weight changes in men with prostate carcinoma both during and after ADT.

    13. Gynecologic Oncology
      You have free access to this content
      Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women (pages 2145–2151)

      Philip E. Castle, Sholom Wacholder, Mark E. Sherman, Attila T. Lorincz, Andrew G. Glass, David R. Scott, Brenda B. Rush, Franklin Demuth and Mark Schiffman

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10927

      Approximately 15% of women who were cytologically negative and tested positive for oncogenic human papillomavirus DNA at enrollment into the study received an equivocal or definitely abnormal Pap test within 57 months of follow-up.

    14. Head and Neck Disease
      You have free access to this content
      Potential marker of oral squamous cell carcinoma aggressiveness detected by fluorescence in situ hybridization in fine-needle aspiration biopsies (pages 2152–2159)

      Ryozo Miyamoto, Narikazu Uzawa, Shunya Nagaoka, Koichi Nakakuki, Yasushi Hirata and Teruo Amagasa

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10929

      The disease-free and overall survival period of patients with CCND1 numerical aberration was significantly shorter than that of patients without the CCND1 numerical aberration. The CCND1 numerical aberration is useful both as a prognostic indicator that is independent of the TNM classification, and an indicator to assist in determination of the appropriate treatment for patients with oral squamous cell carcinomas.

    15. Hematologic Malignancies
      You have free access to this content
      A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients (pages 2160–2168)

      Mohamad A. Hussein, Laura Wood, Eric Hsi, Gordan Srkalovic, MaryAnn Karam, Paul Elson and Ronald M. Bukowski

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10946

      Substituting pegylated liposomal doxorubicin for doxorubicin in the vincristine, doxorubicin, dexamethasone regimen and reducing the dose of dexamethasone in patients with multiple myeloma improve the safety profile and convenience of the treatment regimen without compromising efficacy.

    16. You have free access to this content
      Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy : Long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-a/b multicenter randomized trial (pages 2169–2179)

      Malika Djeridane, Stéphane Oudard, Martine Escoffre-Barbe, Laurence Lacotte-Thierry, Bernard Desablens, Jean Briére, Mamoun Dib, Philippe Cassasus, Christiane Ghandour, Thierry Lamy, Françoise Lejeune, Marc Simon, Catherine Traullé, Magda Vigier, Henri Maisonneuve, Josette Briére, Pierre Colonna and Jean-Marie Andrieu

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10932

      A 12-week regimen of chemotherapy plus extended full-dose irradiation yielded excellent results in patients with advanced or bulky Hodgkin disease.

    17. Hepatobiliary Tract
      You have free access to this content
      Hepatic intraductal oncocytic papillary carcinoma (pages 2180–2187)

      Robert C. G. Martin, David S. Klimstra, Lawrence Schwartz, Asli Yilmaz, Leslie H. Blumgart and William Jarnagin

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10934

      Papillary peripheral cholangiocarcinoma is a rare type of cholangiocarcinoma that includes an interesting variant, intraductal oncocytic papillary carcinoma. These tumors are predominantly found in men, who present with large (> 5 cm) mucinous cystic lesions of the bile duct. A predominantly noninvasive histology is seen, and long term survival may be achieved with complete resection.

    18. You have free access to this content
      Serum endostatin predicts tumor vascularity in hepatocellular carcinoma (pages 2188–2195)

      Dipok Kumar Dhar, Takashi Ono, Akira Yamanoi, Yukiko Soda, Emi Yamaguchi, Md Atikur Rahman, Hitoshi Kohno and Naofumi Nagasue

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10972

      Immunohistochemical expression of endostatin in hepatocellular carcinoma (HCC) appears to have a direct correlation with the serum endostatin level. Measurement of the serum endostatin level may predict tumor vascularity and serve as a promising tool in antiangiogenic therapy for HCC patients.

    19. Lung Disease
      You have free access to this content
      Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma (pages 2196–2201)

      Tsutomu Kawakami, Tetsuji Tokunaga, Hiroyuki Hatanaka, Hiroshi Kijima, Hitoshi Yamazaki, Yoshiyuki Abe, Yoshiyuki Osamura, Hiroshi Inoue, Yoshito Ueyama and Masato Nakamura

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10936

      The co-expression of the neuropilin (NRP) 1 and 2 genes is significantly correlated with tumor progression through neovascularization in nonsmall cell lung carcinoma (NSCLC). Both NRP1 and NRP2 are key molecules for stromal vascularization in association with cell-retained vascular endothelial growth factor isoform in NSCLC.

    20. Sarcoma
      You have free access to this content
      Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? (pages 2202–2210)

      Norman Jaffe, Humberto Carrasco, Kevin Raymond, Alberto Ayala and Farzin Eftekhari

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10944

      Chemotherapy is an integral component in the optimum treatment of osteosarcoma. However, to achieve cure, surgical ablation of the primary tumor also is required.

    21. Discipline

      Epidemiology
      You have free access to this content
      Breast, cervical, and colorectal carcinoma screening in a demographically defined region of the southern U.S. (pages 2211–2222)

      Steven S. Coughlin, Trevor D. Thompson, Laura Seeff, Thomas Richards and Fred Stallings

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10933

      The current study used Behavioral Risk Factor Surveillance System (BRFSS) colorectal carcinoma screening data for 1997 and 1999 and BRFSS breast and cervical carcinoma screening data for 1998–2000 to examine whether screening rates of African-American and white men and women living in the U.S. southern Black Belt demonstrated disparities, and whether they differed from those of persons living in other parts of the U.S. The major finding was that racial differences were less notable than regional differences, with persons living in southern rural areas found to have significantly lower colorectal carcinoma screening rates.

    22. Medical Oncology
      You have free access to this content
      Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies (pages 2223–2229)

      Paula M. Fracasso, Kristie A. Blum, Benjamin R. Tan, Carole L. Fears, Nancy L. Bartlett, Matthew A. Arquette and Romnee S. Clark

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10937

      Combination therapy of pegylated liposomal doxorubicin (PEG-LD) 20 mg/m2 and gemcitabine 2000 mg/m2 on Days 1 and 15 of a 28-day schedule is a well tolerated regimen that minimizes hematologic and skin toxicities. This study describes a Phase I trial undertaken to evaluate the maximum tolerated dose and toxicities of combination therapy with PEG-LD and gemcitabine in patients with advanced malignancies.

    23. You have free access to this content
      Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma (pages 2230–2236)

      Leandro C. A. Cerchietti, Alfredo H. Navigante, Marcelo R. Bonomi, Mariel A. Zaderajko, Pablo R. Menéndez, Catalina E. Pogany and Berta M. C. Roth

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10938

      Mucositis-associated pain following concomitant chemoradiotherapy was alleviated successfully with morphine mouthwash.

    24. Psychological Oncology
      You have free access to this content
      Cancer incidence in parents who lost a child : A nationwide study in Denmark (pages 2237–2242)

      Jiong Li, Christoffer Johansen, Dorthe Hansen and Jørn Olsen

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10943

      Psychological stress after the death of a child was associated with a slightly increased overall cancer risk in mothers in a nationwide follow-up study in Denmark. Smoking-related malignancies were increased after a long follow-up, but no increases were found for breast carcinoma, alcohol-related malignancies, virus/immune-related malignancies, or hormone-related malignancies.

    25. Translational Research
      You have free access to this content
      Peroxisome proliferator-activated receptor γ ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines (pages 2243–2251)

      Kaname Yoshizawa, Daniel P. Cioca, Shigeyuki Kawa, Eiji Tanaka and Kendo Kiyosawa

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10906

      The peroxisome proliferator-activated receptor γ (PPARγ) ligand, troglitazone, induces the cell cycle arrest of hepatocellular carcinoma (HCC) cell lines through hypophosphorylation of retinoblastoma protein by increasing the cyclin-dependent kinase inhibitors, p21 and p27. It also induces apoptosis by caspase-dependent and independent mechanisms. Ligand activation of PPARγ is a possible new therapeutic approach to treat patients with HCC.

  3. Correspondence

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      Serum folate and homocysteine levels in head and neck squamous cell carcinoma (pages 2252–2253)

      Barbara Frick, Katharina Schröcksnadel and Dietmar Fuchs

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10894

    2. You have free access to this content
      Author reply (pages 2253–2254)

      Giovanni Almadori, Francesco Bussu, Jacopo Galli and Gabriella Cadoni

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10897

    3. You have free access to this content
    4. You have free access to this content
      Author reply (page 2255)

      Ivo A. Olivotto and Asako Gomi

      Article first published online: 31 OCT 2002 | DOI: 10.1002/cncr.10960

SEARCH

SEARCH BY CITATION